A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
Condition: Primary Immunodeficiency Interventions: Biological: Gamunex-C; Biological: IVIG-PEG Sponsor: Grifols Therapeutics LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 23, 2020 Category: Research Source Type: clinical trials
